Skip to main content
13260917 Canada Inc. logo

13260917 Canada Inc. — Investor Relations & Filings

Ticker · MSCL TSXV Manufacturing
Filings indexed 256 across all filing types
Latest filing 2020-09-01 Regulatory Filings
Country CA Canada
Listing TSXV MSCL

About 13260917 Canada Inc.

www.satellos.com

13260917 Canada Inc. is the legal predecessor of Satellos Bioscience Inc., a biotechnology company specializing in regenerative medicine for degenerative muscle diseases. The company focuses on Duchenne muscular dystrophy (DMD), utilizing a proprietary scientific approach rooted in restoring muscle stem cell function. Satellos discovered that dystrophin deficiency disrupts muscle stem cell asymmetric division, hindering natural repair. Its core product development involves small molecule therapeutics, such as SAT-3247 (in Phase 2 clinical trials), designed to modulate the AAK1 protein. This modulation aims to reactivate the body's intrinsic muscle repair mechanisms, offering a novel oral treatment strategy for patients with DMD and related conditions.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2020-09-01 English
Interim MD&A - English.pdf
Regulatory Filings
2020-09-01 English
Interim financial statements/report – English.pdf
Regulatory Filings
2020-09-01 English
News release - English.pdf
Regulatory Filings
2020-08-31 English
News release - English.pdf
Regulatory Filings
2020-07-31 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing the first quarter 2020 financial results of iCo Therapeutics. It includes operational highlights, financial results for the quarter ended March 31, 2020, liquidity information, and management changes. The document contains actual financial data such as comprehensive loss, research and development expenses, and cash position. It is not merely an announcement of a report but provides substantive financial information and analysis for a quarterly period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (7264 characters) supports it being a full report rather than a brief announcement or certification. Hence, the appropriate classification is IR with high confidence. Q1 2020
2020-07-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.